AR087346A1 - Formulaciones de compuestos de tiofeno - Google Patents
Formulaciones de compuestos de tiofenoInfo
- Publication number
- AR087346A1 AR087346A1 ARP120102728A ARP120102728A AR087346A1 AR 087346 A1 AR087346 A1 AR 087346A1 AR P120102728 A ARP120102728 A AR P120102728A AR P120102728 A ARP120102728 A AR P120102728A AR 087346 A1 AR087346 A1 AR 087346A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pharmaceutical composition
- formulations
- formula
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describe una composición farmacéutica que comprende: a) una forma polimórfica M o sal de trometamina del compuesto (1) representado por la fórmula estructural (1) y b) un portador de relleno. Un método para preparar una composición farmacéutica que comprende: proveer una mezcla del compuesto de fórmula (1) y un portador de relleno para formar la composición del compuesto de fórmula (1). Un método para tratar una infección por VCH en un sujeto, dicho método comprende administrar al sujeto una cantidad terapéuticamente eficaz de la composición farmacéutica.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161511643P | 2011-07-26 | 2011-07-26 | |
US201161511644P | 2011-07-26 | 2011-07-26 | |
US201161511647P | 2011-07-26 | 2011-07-26 | |
US201161511648P | 2011-07-26 | 2011-07-26 | |
US201161512079P | 2011-07-27 | 2011-07-27 | |
US201161545751P | 2011-10-11 | 2011-10-11 | |
US201261623144P | 2012-04-12 | 2012-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087346A1 true AR087346A1 (es) | 2014-03-19 |
Family
ID=46604098
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102726A AR087344A1 (es) | 2011-07-26 | 2012-07-26 | Formas polimorficas del acido 5-(3,3-dimetil-but-1-inil)-3-[(trans-4-hidroxi-ciclohexil)-(trans-4-metil-ciclohexancarbonil)-amino]-tiofen-2-carboxilico y su uso en el tratamiento de la hepatitis c |
ARP120102728A AR087346A1 (es) | 2011-07-26 | 2012-07-26 | Formulaciones de compuestos de tiofeno |
ARP120102727A AR087345A1 (es) | 2011-07-26 | 2012-07-26 | Metodos para la preparacion de compuestos de tiofeno |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102726A AR087344A1 (es) | 2011-07-26 | 2012-07-26 | Formas polimorficas del acido 5-(3,3-dimetil-but-1-inil)-3-[(trans-4-hidroxi-ciclohexil)-(trans-4-metil-ciclohexancarbonil)-amino]-tiofen-2-carboxilico y su uso en el tratamiento de la hepatitis c |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102727A AR087345A1 (es) | 2011-07-26 | 2012-07-26 | Metodos para la preparacion de compuestos de tiofeno |
Country Status (6)
Country | Link |
---|---|
US (3) | US20140235703A1 (es) |
EP (1) | EP2736893A1 (es) |
AR (3) | AR087344A1 (es) |
AU (1) | AU2012286853A1 (es) |
TW (2) | TW201317223A (es) |
WO (4) | WO2013016491A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
EP2762124A1 (en) | 2013-01-31 | 2014-08-06 | IP Gesellschaft für Management mbH | Packaging comprising administration units of polymorphs, amorphous forms or solvates |
US20150065439A1 (en) * | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
KR102305932B1 (ko) * | 2015-06-29 | 2021-09-28 | 플로로놀 인코퍼레이티드 | 갈조류의 고체 약제학적 조성물 |
BR112023000494A2 (pt) * | 2020-07-10 | 2023-03-28 | Aquafortus Tech Limited | Solução de recuperação de sal e processos de uso da mesma |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU227742B1 (en) | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
WO1999007734A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
EP1003775B1 (en) | 1997-08-11 | 2005-03-16 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
CA2338490A1 (en) | 1998-07-27 | 2000-02-10 | Sergio Altamura | Diketoacid-derivatives as inhibitors of polymerases |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
JP2004509066A (ja) | 2000-05-10 | 2004-03-25 | スミスクライン・ビーチャム・コーポレイション | 新規抗感染症薬 |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
WO2002060926A2 (en) | 2000-11-20 | 2002-08-08 | Bristol-Myers Squibb Company | Hepatitis c tripeptide inhibitors |
ES2532836T3 (es) | 2001-01-22 | 2015-04-01 | Merck Sharp & Dohme Corp. | Derivados de nucleósidos como inhibidores de la ARN polimerasa viral dependiente de ARN |
AU2002252183A1 (en) | 2001-03-06 | 2002-09-19 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
JP2005500287A (ja) | 2001-06-11 | 2005-01-06 | シャイアー バイオケム インコーポレイテッド | Flavivirus感染の処置または予防のための化合物および方法 |
PL208713B1 (pl) | 2001-06-11 | 2011-05-31 | Virochem Pharma Inc | Związek stanowiący pochodną tiofenu, kompozycja farmaceutyczna zawierająca taki związek i jego zastosowanie |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
WO2003026587A2 (en) | 2001-09-26 | 2003-04-03 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitus c virus |
WO2003035060A1 (en) | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
TW200403236A (en) | 2002-04-11 | 2004-03-01 | Vertex Pharma | Inhibitors or serine proteases, particularly HCV NS3-NS4A protease |
US20050069522A1 (en) | 2002-08-12 | 2005-03-31 | Richard Colonno | Combination pharmaceutical agents as inhibitors of HCV replication |
ATE466856T1 (de) | 2002-12-10 | 2010-05-15 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
CN100453553C (zh) | 2003-04-11 | 2009-01-21 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
EP1613620A1 (en) | 2003-04-11 | 2006-01-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
PE20050251A1 (es) | 2003-07-18 | 2005-04-13 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc |
AR045596A1 (es) | 2003-09-05 | 2005-11-02 | Vertex Pharma | Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc |
CA2538791A1 (en) | 2003-09-18 | 2005-03-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
EP2311851A3 (en) | 2004-02-04 | 2011-05-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
BRPI0511834A (pt) | 2004-07-14 | 2008-01-08 | Ptc Therapeutics Inc | métodos por tratar hepatite c |
WO2006039488A2 (en) | 2004-10-01 | 2006-04-13 | Vertex Pharmaceuticals Incorporated | Hcv ns3-ns4a protease inhibition |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US10071416B2 (en) | 2005-10-20 | 2018-09-11 | Nucor Corporation | High strength thin cast strip product and method for making the same |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2009005185A (es) | 2006-11-15 | 2009-07-07 | Virochem Pharma Inc | Analogos de tiofeno para el tratamiento o prevencion de infecciones de flavivirus. |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
EP2250163B1 (en) | 2008-02-12 | 2012-03-28 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP5312486B2 (ja) | 2008-02-13 | 2013-10-09 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2010062821A1 (en) | 2008-11-28 | 2010-06-03 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
BRPI0922364A2 (pt) | 2008-12-03 | 2017-08-29 | Presidio Pharmaceuticals Inc | Composto, composição farmacêutica e uso de um composto |
CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
EP2398474A4 (en) | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
SI2410844T1 (sl) | 2009-03-27 | 2016-06-30 | Merck Sharp & Dohme Corp. | Inhibitorji replikacije virusa hepatitisa C |
TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
KR20100113258A (ko) | 2009-04-13 | 2010-10-21 | 아로 주식회사 | 도전성재질을 이용한 안테나 제조방법과 그 제조방법에 의해 제조되는 안테나 |
EP2419404B1 (en) | 2009-04-15 | 2015-11-04 | AbbVie Inc. | Anti-viral compounds |
MX2011011136A (es) | 2009-04-24 | 2011-11-18 | Tibotec Pharm Ltd | Eteres diarilicos. |
CN102421435A (zh) | 2009-04-28 | 2012-04-18 | 贝林格尔.英格海姆国际有限公司 | 使用PKC-θ抑制剂的免疫性疾病的离体治疗 |
JP2012526834A (ja) | 2009-05-12 | 2012-11-01 | シェーリング コーポレイション | ウイルス疾患治療に有用な縮合型三環式アリール化合物 |
-
2012
- 2012-07-26 AR ARP120102726A patent/AR087344A1/es not_active Application Discontinuation
- 2012-07-26 WO PCT/US2012/048260 patent/WO2013016491A1/en active Application Filing
- 2012-07-26 WO PCT/US2012/048261 patent/WO2013016492A1/en active Application Filing
- 2012-07-26 TW TW101127011A patent/TW201317223A/zh unknown
- 2012-07-26 AR ARP120102728A patent/AR087346A1/es unknown
- 2012-07-26 TW TW101127020A patent/TW201313697A/zh unknown
- 2012-07-26 EP EP12743039.5A patent/EP2736893A1/en not_active Withdrawn
- 2012-07-26 AR ARP120102727A patent/AR087345A1/es not_active Application Discontinuation
- 2012-07-26 WO PCT/US2012/048272 patent/WO2013016501A1/en active Application Filing
- 2012-07-26 WO PCT/US2012/048258 patent/WO2013016490A1/en unknown
- 2012-07-26 AU AU2012286853A patent/AU2012286853A1/en not_active Abandoned
-
2014
- 2014-01-24 US US14/162,997 patent/US20140235703A1/en not_active Abandoned
- 2014-01-24 US US14/163,064 patent/US20140235705A1/en not_active Abandoned
- 2014-01-24 US US14/163,014 patent/US20140235704A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2012286853A1 (en) | 2013-05-02 |
TW201317223A (zh) | 2013-05-01 |
WO2013016492A1 (en) | 2013-01-31 |
WO2013016490A1 (en) | 2013-01-31 |
AR087345A1 (es) | 2014-03-19 |
EP2736893A1 (en) | 2014-06-04 |
US20140235704A1 (en) | 2014-08-21 |
WO2013016501A1 (en) | 2013-01-31 |
WO2013016491A1 (en) | 2013-01-31 |
US20140235705A1 (en) | 2014-08-21 |
AR087344A1 (es) | 2014-03-19 |
US20140235703A1 (en) | 2014-08-21 |
TW201313697A (zh) | 2013-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201500265A1 (ru) | Ингибиторы репликации вирусов гриппа | |
BR112016010080A8 (pt) | compostos de pirazolopirimidina, composição farmacêutica e seu uso | |
BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
CR20140301A (es) | Derivados de betulina | |
MY184306A (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | |
EA201591512A1 (ru) | Борсодержащие молекулы, способы и составы | |
CR20130534A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
NZ739248A (en) | Inhibitors of hepatitis c virus | |
UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
NI201400022A (es) | Composición farmacéutica que comprende un ciclopolisacárido | |
EA201490320A1 (ru) | Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a | |
AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
MA37866A1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
EA201490569A1 (ru) | Полиморфная форма гидрохлорида придопидина | |
AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
BR112015004523A2 (pt) | compostos de tetraciclina | |
AR087346A1 (es) | Formulaciones de compuestos de tiofeno | |
RU2015122032A (ru) | Оксазолидинонсодержащие соединения, композиции и способы их использования | |
TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
EA201791321A1 (ru) | Составы ингибитора lfa-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |